Hims & Hers Health (NYSE:HIMS) Price Target Raised to $25.00

Hims & Hers Health (NYSE:HIMS) had its price target boosted by Bank of America from $21.00 to $25.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have a neutral rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Needham & Company LLC upgraded shares of Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a research note on Monday, March 9th. BTIG Research lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a “hold” rating in a research report on Tuesday, March 10th. Finally, Citigroup upgraded shares of Hims & Hers Health from a “sell” rating to a “neutral” rating and lifted their target price for the company from $13.25 to $24.00 in a research note on Tuesday, March 10th. Three equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $31.86.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $28.74 on Thursday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The stock has a 50-day simple moving average of $19.72 and a two-hundred day simple moving average of $32.28. The firm has a market capitalization of $6.55 billion, a PE ratio of 56.35, a P/E/G ratio of 2.56 and a beta of 2.32. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $70.43.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.02 by $0.06. The firm had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The business’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.11 earnings per share. Analysts forecast that Hims & Hers Health will post 0.29 EPS for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Irene Becklund sold 5,529 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $136,511.01. Following the completion of the transaction, the insider directly owned 8,752 shares in the company, valued at $216,086.88. This represents a 38.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Oluyemi Okupe sold 9,217 shares of the stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $23.77, for a total transaction of $219,088.09. Following the sale, the chief financial officer directly owned 318,789 shares of the company’s stock, valued at approximately $7,577,614.53. This trade represents a 2.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 129,889 shares of company stock valued at $3,230,986 in the last 90 days. 13.71% of the stock is currently owned by company insiders.

Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quent Capital LLC bought a new position in shares of Hims & Hers Health during the 3rd quarter valued at about $28,000. Flagship Harbor Advisors LLC purchased a new position in shares of Hims & Hers Health during the fourth quarter valued at about $28,000. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health in the third quarter worth about $28,000. Bogart Wealth LLC increased its holdings in shares of Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the last quarter. Finally, Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health in the first quarter worth about $30,000. 63.52% of the stock is currently owned by institutional investors.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Regulatory catalyst — the FDA has begun a formal review process and scheduled advisory meetings to consider allowing compounding pharmacies to make several popular peptides, which could expand addressable market for Hims if it participates in peptide products or distribution. Hims rises as FDA considers broader peptides access
• Positive Sentiment: Investor enthusiasm and coverage lift — multiple outlets tied comments from RFK Jr. and the FDA step to a clearer path for peptide access, helping the stock to rally as traders price in new revenue opportunities. Hims jumps as RFK Jr. seeks to loosen peptide regulations
• Positive Sentiment: Street reaction — Bank of America raised its price target to $25 (from $21) citing the peptide review as a potential long‑term tailwind, a move that helped validate the bull narrative even though the rating stayed Neutral. BofA Raises Hims & Hers Target to $25
• Neutral Sentiment: Momentum/volume — the stock has seen an intraday surge with above‑average volume, but some analyst notes warn that recent EPS/estimate revisions may not guarantee sustained upside. Monitor whether revisions follow through. Hims & Hers Soars 11.1%
• Neutral Sentiment: Valuation questions — commentary urging a reassessment of HIMS highlights sharp short‑term moves and mixed longer‑term returns; valuation metrics and elevated beta increase sensitivity to news flow. Is It Time To Reassess Hims & Hers?
• Negative Sentiment: Short interest / hedge fund activity — Cedar Grove Capital disclosed a profitable short stance and highlighted downside in its investor letter, underscoring persistent bearish views among some investors. Cedar Grove Capital Benefitted from Short Position
• Negative Sentiment: Broader fundamental concerns — coverage noting that HIMS has fallen substantially over recent months and faces margin and cash‑flow pressure suggests downside risk remains if regulatory optimism fades or execution slips. HIMS Plunges 51.2% in 6 Months

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.